FORCE conducts surveys and partners with researchers who conduct surveys to better understand and address the needs of our community. By participating in surveys for which you are eligible, you help promote and advance hereditary breast and ovarian cancer research.
Please take a moment to view the open surveys below, and consider participating if you are eligible.
Please take this quick survey (it takes about 10 minutes). and share your thoughts on research on uterine cancer risk in BRCA mutation carriers! This survey is a tool of the ABOUT Network led by FORCE. The goals of the ABOUT Network are to collect and measure real-life experiences, questions, decisions, and health outcomes of people like you who are concerned about or living with a cancer-causing mutation or hereditary cancer risk.
Women who are at high risk for breast cancer are recommended to undergo increased breast surveillance. Women who elect screening for risk-management have unique needs for support, resources and information. The purpose of this survey is to better understand and characterize the needs of this section of our community.
This survey will help us improve care and information for women undergoing heightened screening for breast cancer. Once completed, the results of this survey will be shared with the FORCE community.
FORCE is collaborating with researchers from Georgetown University and conducting a brief (15 minute) anonymous survey in order to better understand and address the needs of young previvors with a BRCA mutation or family history of cancer. Participation in this survey is voluntary and is limited to high-risk women age 18 - 25 with a BRCA mutation or family history of cancer who have never been diagnosed with cancer.
Researchers are considering studies using medication or salpingectomy (removal of the fallopian tubes) to lower ovarian cancer risk in high-risk women. FORCE is partnering with researchers to understand more about women's attitudes about participating in ovarian cancer prevention studies.
Update: This survey is now closed. Results from the survey will be presented by researchers from MD Anderson Cancer Center as a poster at the Society of Gynecologic Oncology annual meeting in March, 2013 in Los Angeles.
There is a need for more treatment options for hereditary cancer, and the need is dire for women with metastatic hereditary breast cancer who make up a small subset of the larger breast cancer population. To better understand the nature of hereditary breast cancer and to advocate for more research and better treatment options, FORCE is conducting a brief survey for women who have received a diagnosis of metastatic hereditary breast cancer. This survey is open to women who:
- have a BRCA mutation or breast cancer runs in their family
- have been diagnosed with stage IV (metastatic) breast cancer
Participants who provide contact information at the end of the survey will receive updates about new research, information and programs for women with metastatic hereditary breast cancer.
To better understand the needs of high-risk men, FORCE is conducting a survey and developing a contact registry for men with BRCA mutations or their relatives.
We encourage individuals who meet the following criteria to complete the survey:
- Men from families with strong history of cancer but no known mutation.
- Men who have tested for a BRCA mutation.
- Men from families that have a known BRCA mutation (whether or not they have had testing).
- Women from families with a BRCA mutation
Participants who register for the contact registry at the end of the survey will receive updates about new research, information and programs for men with BRCA mutations.
Update: Preliminary results of this survey have been published in the journal Familial Cancer.
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.